b) to evaluate, in children and adolescents at T1D diagnosis not yet vaccinated against SARS-CoV-2 disease, the frequency of IgM- and IgG-SARS-CoV-2 antibodies during the pandemic period, comparing the relative results to those found in a population of healthy subjects (CTRL). This evidence concerns the gene CD40LG and type 1 diabetes mellitus.